Wonderful to see Klaus Rajewsky honored with the first ever EFIS Lifetime Achievement Award! #iIUIS2025 in Vienna.
Thrilled to share that my #ERCCoG EICO-CODE has been selected for funding!🚀 We will study how eicosanoids shape T cell immunity across tissues. 🧬🔬🧪✨ I am deeply grateful for this recognition of the team’s work - and to everyone supporting us in our research. Exciting years ahead!
Very happy to join the team of the CRC 1479 initiative for the 2nd funding period to study mechanisms of immune evasion in cancer! www.sfb1479.uni-freiburg.de/news/great-n...
Idoyaga and colleagues suggest that pDCs can lose the ability to secrete IFN-I and acquire the transcriptional, epigenetic and functional features of cDCs. Read it here: rdcu.be/eBB5e
www.nature.com/articles/s41...
I had the pleasure of presenting concepts of T cell immunity and our work on cancer immune evasion at the @dgfi-org.bsky.social Spring School in Ettal, Bavaria. Inspiring talks & great exchanges with talented junior researchers across Germany—thank you for the invitation! #dgfispringschool
🍾Many congratulations to former PhD student Philippa Meiser - now Postdoc with Laura Mackay @thedohertyinst.bsky.social - for receiving this years PhD award 🥇 from @dgfi-org.bsky.social at @iuis-online.bsky.social !
🚨Our lab has a new review article out today!
We revisit prostaglandins in cancer—how they’re produced, how PGE₂ reshapes immune responses in tumors, and what this means for future therapies.
Work led by team members Erik Müller & Bastian Kruse @bkru.bsky.social
🔗 doi.org/10.1182/bloo...
Excited to share our new collaborative study with the Sebastian Kobold lab! www.nature.com/articles/s41...
By deleting the PGE2 receptors EP2/EP4, we render CAR T cells resistant to suppression in solid tumors - boosting persistence and anticancer activity in preclinical models and patient samples.
Interesting study by @reisesousalab.bsky.social, highlighting functionally distinct states of activated cDC1s in tumors. 🔬🧪
